Lynparza – media

AstraZeneca’s PARP inhibitor gains market edge with breast cancer approval

AstraZeneca still enjoys the perks of being first to market with its PARP inhibitor. Lynparza (olaparib) sales were $81 million from July to September, whereas net revenues were $16.8 million and $39.4 million for Clovis Oncology Inc.'s Rubraca (rucaparib) and Tesaro Inc.'s Zejula (niraparib), respectively.
- Source: Biopharmadive
- 591
- January 17, 2018
inhibitor Lynparza New Approvals
FDA approves first treatment for breast cancer with a certain inherited genetic mutation

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.
- Source: finance.yahoo
- 558
- January 15, 2018
breast cancer Lynparza metastasized New Approvals
AZ, Merck link to develop and commercialise cancer drugs

AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
- Source: pharmatimes
- 500
- July 31, 2017
cancer Lynparza Market Views Researches therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.